FDA's Science Board To Review Comparative Effectiveness, Pharmacovigilance, Nanotech
This article was originally published in The Pink Sheet Daily
The May 20 meeting follows a recent reorganization of the safety functions in the Center for Drug Evaluation and Research.
You may also be interested in...
Among 2010 accomplishments, FDA’s Office of Cosmetics and Colors completed investigations into lead in lipstick and asbestos in talc, Director Dr. Linda Katz said during the Personal Care Products Council’s Regulatory Science Summit April 13 in Washington.
Despite a $37.6 billion overall cut in federal government domestic spending, a compromise fiscal 2011 funding agreement gives FDA about $107 million more dollars, totaling about $2.46 billion, compared to 2010.
Elevation of the Center for Drug Evaluation and Research’s Office of Surveillance and Epidemiology to a “super-office” is expected to provide greater management support to the drug safety unit’s growing number of staff and responsibilities.